$BWAY News
Last published 3d ago
- 3d agoBWAYBrainsWay Reports Third Quarter 2026 Financial Results and Operational HighlightsGlobeNewswireRevenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million
- 1w agoBWAYBrainsWay Announces Strategic Collaboration with Mindful Health SolutionsGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Nov. 02, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation
- 2w agoBWAYBrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation
- 2w agoBWAYBrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million LivesGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Oct. 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation
- 3w agoBWAYBrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical GroupGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced non-invasive neurostimulation
- 1mo agoBWAYBrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered LivesGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation
- 2mo agoBWAYBrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™GlobeNewswirePeer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity BURLINGTON, Mass. and JERUSALEM,
- 2mo agoBWAYBrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal IdeationGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Aug. 27, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today
- 3mo agoBWAYBrainsWay Second Quarter 2026 Earnings Conference Call - BRAINSWAY LTDEarnings Call TranscriptsGood morning, everyone. My name is Sachi, and I will be your conference operator today. At this time, I would like to welcome everyone to BrainsWay's second quarter 2026 financial results conference call. All lines have
- 3mo agoBWAYBrainsWay Reports Second Quarter 2026 Financial Results and Operational HighlightsGlobeNewswireRecord second quarter 2026 revenue increased 35% to $17.1 million, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding to 20% Remaining performance
- 3mo agoBWAYBrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireBURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation
- 3mo agoBWAYBrainsWay Announces Strategic Investment in Radial Health, Inc.GlobeNewswireBURLINGTON, Mass. and JERUSALEM, July 20, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation
- 4mo agoBWAYBrainsWay Announces Minority-Stake Investment in Sound Minds BehavioralGlobeNewswireBURLINGTON, Mass. and JERUSALEM, July 16, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation
- 4mo agoBWAYBrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive DisorderGlobeNewswireNearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD ~83.5% of
- 4mo agoBWAYBrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered LivesGlobeNewswireBURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation
- 5mo agoBWAYBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual MeetingGlobeNewswireBURLINGTON, Mass. and JERUSALEM, June 09, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the presentation of
- 5mo agoBWAYBrainsWay Announces Minority-Stake Investment in Hopemark HealthGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for
- 6mo agoBWAYBrainsWay First Quarter 2026 Earnings Conference CallBRAINSWAY LTDEarnings Call TranscriptsGood day and welcome to Brainsway First Quarter 2026 Honing Conference Call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key fo
- 6mo agoBWAYBrainsWay Reports First Quarter 2026 Financial Results and Operational HighlightsGlobeNewswireRevenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over 100% year-over-year to $2.3 million for Q1 2026 Adjusted EBITDA for Q1 of 2026 more than doubled year-over-year to
- 6mo agoBWAYBrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026GlobeNewswireBURLINGTON, Mass. and JERUSALEM, April 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today
- 7mo agoBWAYBrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) TherapyGlobeNewswireBURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for
- 7mo agoBWAYBrainsWay to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireBURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for
- 7mo agoBWAYBrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDDGlobeNewswireBURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for
- 8mo agoHELPACHCJNJBWAY+1Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar ExpansionPR NewswireMarket News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news...
- 8mo agoBWAYLandmark Data Validate BrainsWay's SWIFT™ Deep TMS, Beginning a New Era in Depression TreatmentGlobeNewswireBURLINGTON, Mass. and JERUSALEM, March 04, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled new clinical data showing a significantly faster, noninvasive way to treat depression without
- 8mo agoBWAYBrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today
- 8mo agoBWAYBrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access DayGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 8mo agoBWAYBrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.GlobeNewswireBrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026
- 8mo agoBWAYBrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to CareGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 8mo agoBWAYBrainsWay Announces Change in ADS-to-Ordinary Share RatioGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 9mo agoBWAYBrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 10mo agoBWAYBrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 10mo agoBWAYBrainsWay Announces First Coverage Policy for Accelerated Deep TMS™GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Jan. 07, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 10mo agoBWAYBrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 11mo agoBWAYBrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 12mo agoBWAYBrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use DisorderGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Nov. 17, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive brain stimulation technologies, today
- 1y agoBWAYBrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 13, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments
- 1y agoBWAYBrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use DisorderGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental
- 1y agoBWAYBrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025GlobeNewswireBURLINGTON, Mass. and JERUSALEM, Oct. 28, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental
- 1y agoBWAYBrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health ProvidersGlobeNewswireRecent agreements with two additional U.S. mental health providers bring total to four in 2025 Strategy seeks to drive long-term shareholder value BURLINGTON, Mass. and JERUSALEM, Oct. 27, 2025 (GLOBE NEWSWIRE) --
- 1y agoBWAYHYFTICADAMCSMindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth StrategyBusiness WireMindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO),
- 1y agoBWAYBrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)GlobeNewswireClinical data shows that BrainsWay's new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response and remission The accelerated protocol is now commercially available
- 1y agoBWAYBrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd.GlobeNewswireThis investment marks BrainsWay's entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief's breakthrough Proliv™Rx device is pending
- 1y agoBWAYBrainsWay Acquires Minority-Stake in Axis Integrated Mental HealthGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental
- 1y agoBWAYBrainsWay Ltd. (BWAY) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoBWAYBrainsWay Reports Second Quarter 2025 Financial Results and Operational HighlightsGlobeNewswireAchieved record quarterly revenue of $12.6 million in Q2 2025, an increase of 26% compared to Q2 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.5 million, Raised full-year 2025 Revenue and
- 1y agoBWAYBrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health ProfessionalsGlobeNewswireBURLINGTON, Mass. and JERUSALEM, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its
- 1y agoBWAYBrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025GlobeNewswireBURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental
- 1y agoBWAYBrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)GlobeNewswireBURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today
- 1y agoBWAYBrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San DiegoGlobeNewswireBURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, proudly